title: Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey.
abstract: BACKGROUND
  Desmopressin (DDAVP) testing (DT) in patients (pts) with haemophilia A (HA) and carriers (CHA) is up to now not standardized. This prompted us to evaluate results of DT carried out between 1996 and 2011 in centres of the Competence Network Haemorrhagic Diatheses East.
  
  
  METHODS
  An increase of the factor VIII activity (FVIII) above 50% or at least the two fold of initial values within 120 min after DDAVP was defined as complete response (CR). Data from 80 patients (31 children, 49 adults) of whom 64 suffered from HA (sub-HA: n=48; mild: n=14; moderate: n=2) and 16 patients CHA were evaluated.
  
  
  RESULTS
  In 34 patients DDAVP was given i.v. (dose range: 0.26-0.6 µg/kg body weight, mean: 0.33), in 31 intranasally (i.n. 300-600 µg) and in 15 s.c. (15-40 µg). The maximal FVIII increase was reached 60 min after DDAVP. For i.v. application the mean FVIII increase was 3.1-fold, for i.n. 2.1-fold and for s.c. 2.4-fold. A CR was detected in 71 patients, a non-response in 9. Mild side effects such as flush, headaches or nausea were observed in 11 patients (14%).
  
  
  CONCLUSIONS
  For desmopressin testing in patients with haemophilia A and carriers i.v. application at 0.3 µg/kg body weight and the determination of FVIII before and 60 min after desmopressin infusion is recommended.
authors.affiliation: Department of Paediatric Haematology, Oncology and Haemostaseology, University Hospital Carl Gustav Carus, Dresden, Germany. ralf.knoefler@uniklinikum-dresden.de
authors.forename: R
authors.initials: R
authors.lastname: Knöfler
authors.forename: J
authors.initials: J
authors.lastname: Koscielny
authors.forename: J T
authors.initials: JT
authors.lastname: Tauer
authors.forename: B
authors.initials: B
authors.lastname: Huhn
authors.forename: A
authors.initials: A
authors.lastname: Gneuss
authors.forename: E
authors.initials: E
authors.lastname: Kuhlisch
authors.forename: A
authors.initials: A
authors.lastname: Hofmann
authors.forename: S
authors.initials: S
authors.lastname: Petros
authors.forename: V
authors.initials: V
authors.lastname: Aumann
authors.forename: D
authors.initials: D
authors.lastname: Franke
authors.forename: K
authors.initials: K
authors.lastname: Kentouche
authors.forename: G
authors.initials: G
authors.lastname: Syrbe
authors.forename: K
authors.initials: K
authors.lastname: Seeger
authors.forename: H
authors.initials: H
authors.lastname: Haberland
authors.forename: R
authors.initials: R
authors.lastname: Klamroth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003894:Deamino Arginine Vasopressin / Q000097:blood*; D005169:Factor VIII / Q000032:analysis*; D005260:Female; D005858:Germany / Q000453:epidemiology; D006467:Hemophilia A / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; C078147:F8 protein, human; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin